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Abstract
Some ruthenium(III) complexes with aryl-azo 2,4-petandione as eo-ligands (LH L3H2) hav.e
been synthesized and characterized spectroscopicallyOR, ’H NMR, UV/Vis, ESR, conductime_tric)
along with elemental analysis and FAB-mass data. Their luminescent and redox properties have
been studied. The antibactei’ial, anti-HIV and antitmnour activities have also been reported.
Introduction
Study of oetahedral ruthenium complexes using spectroscopic techniques is of current interest [1-
4]. Lahiri et al. [5] synthesized several ruthenium(Ill) complexes of N, O donors and studied their
electronic and electrochemical properties. The complexes of Ru(N-N)2C12 family. (where N-N
2,2’-bipyridine and 1, 10-phenanthroline) have been found [6] unsuitable in vew of isomeric
problems. Therefore, several research groups have focussed their attention on the complexes of the
type [Ru(tpy)2]
2+ family (tpy 2, 2’:6’, 2"-terpyridine) in spite of the fact that they exhibited less
favourable photophysieal properties particularly showed weak luminescence at room-temperature
with shorter excited-state lifetime. However, suitably substituted terpyridyl complexes especially
4’-substituted terpyridyl Ru(III) complexes were found to display room-temperature luminescence.
Thus, in order to avoid isomeric complexities, we selected a terpyridyl type tridentate ligand vz.
2,6-bis(2’-benzimidazolyl)pyridine. Thes selectivity of the benzimidazolyl terpyridyl ligand was
also based on its involvement in the strong intramoleeular stacking interactions between the DNA
strands hence in bioactivities [7] ofthe resulting complexes.
In this context it is also of worth to mention that azo/hydrazo compounds have also been subjected
[8] to many biological reactions such as in protein synthesis inhibition, nitrogen fixation and
antitumour properties which have been understood in their action as DNA erosslinking agents.
Additionally, ruthenium(Ill) chloro complexes have been reported [9] to bind covalently to calf-
thymus DNA. In this context reports [10-11] by Keppler and Sava et al. on the tumour inhibiting
properties ofruthenium(Ill) ehloro complexes have been found very encouraging.
Thus in view of above mentioned properties and in continuation to our earlier studies [12-14], we
found it worthwhile to synthesize, new mono and dinuelear Ru(III) chloro complexes containing
aryl diazo-pentane 2,4-dione and 2,6-bis-(2’-benzimidazolyl) pyridine as ligands and to study their
spectroscopic, electrochemical, luminescent and antibacterial/antitumour/anti-HIV properties.
Materials and Methods
All the solvents purchased from E. Merck were distilled using standard procedure prior to use.
Pentane2,4-dione, aniline, p-phenylenediamine, benzidine, RuCI.3H20, 2,i-_pyridine dicarboxylic
acid purchased from Sigma-Aldrich were used_as su_ppli.ed whereas 2,6-bis(2’-benzimidazolyl)
py_fidme was prepared by a reported [15] procedure. Te-trabutyl ammonium bromide taken frtm
Merck was converted into tetrabul ammonium perehlorate (TBAP) by available procedure
[16]. Caution! TBAP could be explosive so the use of small mounts or it are recommended.
Neutral alumina for column chromatography was supplied by E. Merck and used as such. All the
reactions were carried out underN2 atmosphere.
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Microanalysis (C, H and N) performed on a Carlo Erba Elemental Analyzer 1105 and FAB-mass
_data using a JEOL SX-102 mass spectrometer were carried out at the Central Drug Research
Institute Lucknow, India. IR (KBr p_ellets) and LW/Vis data were obtained using a JASCO FT IR
5300 spectrometer and a Shimadzu UV-1601 speetrophotometer whereas ESR spectra in the solid
state_ as well as in solution (DMSO) at room temperature and liquid N2 temperature were recorded
at the Indian Institute of Technology, Mumbai, India. Eleetroefiemical measurements were made
using an electrochemical interface SI1287 potentios.tate, using a graphite disc as working electrode,
platinum wire as auxiliary electrode and Ag/Ag as reference electrode in a three electrode
configuration. Luminescent spectra were reetrdd at the University of Tokyo, Japan using a
Shimadzu RF 5300 speetrophotometer at 25C. The antibacterial study was carried out at the
School of Biotechnology, B.H.U., Varanasi, India whereas antitumour and anti-HIV activities were
evaluated at the School-bfPharmacy, University ofNorth Carolina, USA.
Svnthesis of liands
-,,ealigands (L’H LaH2) (scheme 1) were synthesized and characterized using IR, H/ C NMR,
H- C HMBC (heteronuelear multiple bond correlation setroseopy) and FAB-mass data as
reported [12] by us whereas 2,6-bis(-2’-bermTimidazolyl) pyr!dine was prepared from 2,6-pyridine
dicarboxylie acid and o-phenylenediamine in acidic media following the reported procedure [i 5].
L H HC CI- I-C
L*H
o<C, o<C, ,%0
O HH 0 c n,c c HC C
nolfo L nx (Hymof
Scheme Structure ofligands
Table I: Physical and analytical data of Ru(III) complexes
Complex Yield,% Analysis talc. (Found) % CI A
FAB-mass data (colour) %C %H %N Calc. (’]- cm
2 mol")
Calc. (Found) ,(Found)
[Ru(L’H)3]3C1’ 50" 46.26 4.6 9.81 14.82 280
784.5 (784) (Dark (46.08) (4.54) (9.69) (14.65)
[M-CIT brown)
[RuffLH2)C16(HO)] 55 24.58 2.82 7.17 27.27 28
781 .(781) (Light (24.82) (2.95) (7.08) (26.96)
[MK brown)
[Ru2(LH)C16(DMSO)] 62 31.93 3.48 5.73 21.81 36
977 (977) (Redish (31.65) (3.40) (5.62) (21.50)
[M] brown)
[RuffLH)(Hbbip)DMSO] 58 39.06 3.05 9.96 224
(PF6)9.
838 (838) (Light (39.46) (3.18) (9.85)
[M-PF.] brown)
[RuL"H(Hbbip)C12] 60 42.82 2.77 12.95 4.69 236
(PF6)2
1223(12222+) (Dark (42.95) (2.84) (12.78) (4.86)
[M-2PFt| brown)
Synthesis of comt)lexes
[Ru(LH)3] 3C1 f: An a.queous ethanolic solution (10 mL, 1:1 v/v,) of RuCls.3HO (3mM, 0.784g)
was mixed to an ethanohc solution (10 mL) of the free ligand L’H (3 mM, 0.612g) in 1:1 molar
ratio while stirring and the resulting mixture was refluxed for 28 hours. The pr.ogr.ess of the
reaction was monitored using TLC. The volume of the solvent was reduced to halfwhich was then
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kept in refrigerator for overnight. The brown precipitate thus obtained was filtered and washed
with H220, EtOH followed by_EtzO ,arid then dried in vacuo.
[Ru(L He) C16.2HzO] 2 and Ru(L H2) C16 (DMSO)2] 3 were also prepared as reported above by
refluxing separately an aqueous ethanolie solution (10 mL, 1:1 v/v) ofRuC133HO(6 mM, 1.575g)
with an ethanolic solution (10 mL) of e eorrespp_nding free ligands L H [(3mM, 0.99g) .in
aqueous ethanol (10 mL, 1:1 v/v)] and (L H2) [(3 mM, 1.218g) in-DMSO (15 mL)], respectavely
for 24hours.
.[Ru(LH) (H2bbip) DMSO] (PFt)2 4: To the solution of 1 (0.1 mM, 0.820g) in DMSO (10 mL) a
hot ethanolic solution (10 mL) of free ligand (H2bbip) (0.1 mM, 0.31 lg) was added while stirrmg
and the resulting solution was refluxed for 25 hours then cooled at room temperature and filtered.
The clear filterate thus obtained was precipitated by the addition of saturateda.eous solution of
NH4PFt. The reddish-brown precipitate thhs obtaitied was filtered and washed with HO, EtOH
and Et20 successively and fina]ly dried in vacuo.
Similarly_ [Ru(L H) (Hzbbip)z CI] (PF6)2 5 was also prepared by the addition of a solution of 2
(0.1 mM, 0.781g) in DMSO(10 mL) to a hot ethanofie solution (10 mL) of the ligand (H2bbip)
(0.2 mM, 0.622g) while stirring. After refluxing for 30 hours the solution was cooled at room
temperature and then filtered arid the solid complex as PF6- salt was obtained by_ the addition of
saturated aqueous solution ofNH4PF which was solated and purified as described for 4.
.The elemental analysis and FAB-mass data alongwith other properties of the complexes are shown
n Table I.
Results and Discussion
The composition of the complexes assigned on the bases of their elemental (C, H and N) analysis
and FAB-mass data is shown in Table I. The complexes were found thermally stable at room
temperature. Complexes 1, 4 and 5 were soluble in acetone, acetomtrile, DMF and DMSO whereas
2 and 3 were soluble only in DMF and DMSO. The molar conductance of the complexes shown in
Table I is in consistence with the number ofcounteranions present in the complexes 12,17].
IR Spectra: In the IR spectra (KBr) of the complexes, peaks observed at 1620 1640 cm due to
vC=O were found to be lower as compared to free ligands values observed at 1674-1687 cm. This
indicated the participation of both the >C=O groups in the bonding with ruthenium. However in
complexes 3, 4 strong peak observed at 1102-1108 cm-
was assigned to S-coordinated DMSO in
view of an earlier report [18]. A strong and sharp peak observed at 839-840 cm in the spectra of
thHe
complexes 4 and 5 was assigned to v(PF6").
NMR spec,tra: To get further structurdl support from H NMR spectra, one representative
complex [Ru(L’H)3] 3C1 was reduced into the Ru(II) form in the presence of N-ethyl morpholine
using a reported procedure [19]. The H NMR spectnnn recorded in DMSO-de showed two peaks
at 8 2.6 and 2.9 ppm due to methyl protons, a complex pattern at 7-8 ppm due to phenyl protons
and a singlet at b 14.20 ppm due to theNH proton.
Table II: UVNis and Luminescent data of Ru(III) complexes in DMF (105M) solution
1 [Ru(LH)3]3C1
Complex
2 [RuE(LEHE)C16(H20)2]
3 [Ru2(L3H2)C16(DMSO)2]
4 [Ru2(L1H)(Hbbip)(DMSO)] (PF6)2
5 [RuE(LEHE)(Hbbip)2Cl2] (PF6).
x, nm (lffe, Mtcm) m, nm
269 (21.3) 460.00
357 (22.9)
593 (4.72)
265 (21.50) 436.00
395 (15.16)
550 (8.42)
267 (33.40) 555.00*
423 (67.70)
604 (2.00)
272.50 (17.40) 370, 719
342.50 (32.70)
590.00 (2.00)
269.50 (50.20) 375,725
334.50 (40.30)
540.00 (4.00)
kx was 330 nm except in case of3 where excitation wavelength was 430 nm.
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(PF6)2
Figure 1" Proposed structure of Ru(III) complexes.
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UVNisible spectra: UV/Vis spectra of the mthcnium(III) complexes in DMF solution (10SM)
wcrc recorded in the region 200-800 nm and the spectral data arc listed in Table II.
The data reported in Table II show mainly three transitions in the range 265-272; 334-423 and 540-
604 nm. The former two transitions in the higher energy regions wcrc considered to be ligand
centered (LC) and latter transition in the range 540-604 nm was assigned to ligand (*) to metal
(t2sg) transition in view of earlier reports [4, 5] on ruthcnium(III) systems. Substitution of chloro
groups in the complex 2 by 2,6-bis(2’-bcnzimidazolyl) pyridinc lowered the LMCT transition
wavelength by 10 nm which is also consistent with the earlier report [20]. Almost double intensity
of the peak observed for complex 5 as compared to complex 4 could bc considered duc to the
dinuclcar nature [21] ofthe complex 5.
ESR Spectra: ESR spectra of the complexes wcrc recorded in solid and solution (DMSO) states at
room tcmpcraturc and liquid N2 temperature. The ESR spccmtm of the dinuclcar complex
[Ru2(L2H2) CI(H.O)2] in the solid state shows six well resolved signals. The g values calculated as
1.80-2.50 wcrc found to lic in the range as reported earlier [22,23]. All the peaks were observed
with equal spacing and equal intensity. However for the complexes 1 and 3 a broad spccmnn was
observed in the solid state at 298 K and 77 K temperatures but in solution (DMSO) they showed
thrcc signals and g values, again calculated to bc in the range 1.9-2.5.
Thus on the basis of spectroscopic data (IR, 1H NMR, UV/Vis, ESR, conductimctric) alongwith
elemental analysis and FAB mass data, the proposed structures for the complexes arc shown in
Figure 1.
Redox properties: Rcdox properties of the ruthenium complexes have bccn studied in DMF
solution (10-M) in the potential range +2V using Ag/Ag
/ as reference and graphite disc as working
and Ag/Ag* as rcfcrcncc clcctrodcs. Rcdoxpotential (E) data arc reported in Table III.
Table lII: Electrochemical data ofthe Ru(III)complexes
Complexes Oxidations potential Reductions potential
E (V) E (V)
"i [Ru(LH)]3C|’
2 [Ru2(L2H2)C16(H20)2]
3 [Ru2(LH2)CI6(DMSO)2]
4 [Ru2(LIH)(Hbbip)(DMSO)] (PF6)2
5 [Ru2(L2H2)(Hbbip)2C12](PF)
+’1. i5, 4-0.82 -0.86,-1.37
+1.20 -7.24, -1.40
+1.40, +1.20 -0.86, -1.51
+ 1.12 -0.79,-1.44,-1.70
+1.10 -0.72, -1.46, -1.80
i Obtained in DMF Solution (10M)"eontaining 0.i mol+ dm"IBu4N]C104 a.s supporting
electrolyte and _potentials were determined wifh Ag/Ag as reference and platinum wire
as an auxiliary electrode at room temperature and 200 mWs scan rate.
Oxidation
Cyclic-voltammogram of the mononuclear complex showed two irreversible oxidations at +0.82
and +1.15 V. Since free ligand also showed an oxidation peak at /1.00 V so distinction between
ligand-based and metal-based oxidation was difficult. However in view of earlier report [24] the
latter peak at 1.15 V could be considered to arise from Ru(III) --, Ru(IV) oxidation further more
dinuclear complex [RuEL H2C16(DMSO)2] showed two oxidation peaks at +1.40 and 1.20 V which
could arise due to subsequent oxidation oftwo ruthenium centres.
Other complexes showed only one broad oxidation peak indicating that ligand based oxidation is
overlapping with the metal-based oxidation.
Reductions
The complexes 1 3 showed two reduction peaks in the range -0.72 to -0.86V and -1.37 to 1.51 V
whereas complexes 4 and 5 showed three reduction peaks in the range -0.72 to -0.79, -1.44 to
1.46V and-1.80 to-1.79V which were consistent with earlier report [25].
Room temperature emission spectra
Emission properties of the complexes have been studied in DMF solution (10
5 M) at room
temperature and the data are presented in Table II. The complexes 1 3 after excitation at 330 nm
emitted at 460, 436 and 555 nm respectively indicating that the dinuclear complex 3 emitted at
lower energy than the complexes 1 and 2. The complexes 4 and 5 showed two emissions at 370,
719 and 375, 725 nm respectively. In view of an earlier report [26] two emissions in the range 370
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375 and 719-720 rim were considered to arise probably from bridging ligand to metal and
terminal ligand to metal charge-transfer. The better luminescence observed for the mononuclear
complex 4 as compared to dinuclear complex 5 was also found to be consistent with the earlier
report [27].
Antibacterial studies
The antibacterial activity of the ruthenium (II,I) complexes was evaluated against Pseudomonas
aeruginosa and E. coli in DMSO solution (10"M) using the susceptibility testing method [28] as
reported earlier [12]. Inhibitory effects by the free ligands (LH-L3H2) against Pseudomonas
aerugmosa have been discussed earlier [12] by us. The data shown in Table IV indicate that the
ruthenium complexes are more active against E.col as compared to Pseudomonas aeruginosa.
Tabl IV: Antibacterial activity of Ru(!II) omplexes
Compound
Pseudomonas aerugmosa
"[gu(i .I-I)313ci’ 0’.25
[Ru2(i ,.’H2)C16(H20)2] 0.19
[Ru2(I ,H2) C16 (DMSO)2] 0.30
[Ru([ H)(Hbbip) (DMSO)] (PF6) 0.22
[Ru(I H2)(Hbbip.)2 C12] (PF6)2 0.20
conzentrat0n 0f Samples was 10’ lxM n DMSO andinhibition zones
subtracting the inhibition by the free solvent (DMSO) used as control.
Zone of Inhibition (em,),
0.55
0.50
0.75
0.60
0.48
were measured
Antitumour and Anti-I-llV studies
The antitumour and anti-HIV activities were evaluated using standard procedures [29, 30]. The
cytotoxicity data of free ligands (L,H L3H2) alongwith their ruthenium complexes are shown in
Table V. Among the free ligands (L’H LaH2),_the activity trend was observed to be L3H2 > LiH >
L2H2 indicating that the dinueleating ligand LH2 was most active as compared to L2H2 against
both tumour cells viz. A549 and U87-MG. However, the antitumour activity of ruthenium (III)
complexes 1-5 was found to be significant as compared to their free ligands. The highest activity
was shown by complex 3 which contains the most active ligand (L3H2) against both the turnout
cells. The mononuclear complex I showed better activity as compared to dinuclear complex 2. The
better activity of complex 4 as compared to complex 1 against U87-MG was considered in terms of
the presence of the bio-active benzimidazolyl group. The complex 5 did not show activity against
any of both cells however it had a significant effect on the growth of only the glioblastoma cell line
(clumping behaviour). A detailed mechanism ofthese activities is yet to be explored.
The anti-HIV activities (Table V) trend of the free ligands were again in the sequence L3H2 > LH
> L2H2 indicating that the ligand L3H2 was the most active. However ruthenium (III)complexes
showed a better activity as compared to the free ligands. The activity of these compounds was
compared with the standard AZT (azido-thymidine) treated as control under the similar
experimental conditions.
Table V: Antitumour and anti-HIV activities of free liands and their Ru(III)...e0mplexes.
Compound Tumour cells Anti-HIV
A549 U87-MG ICs0.(lag/mL)
LH >20 (16) > 20 (9.1) 22.00
LH2 > 20 (10.2) NA 25.30
L3H 14.4 11.5 21.80
1 > 20 (26.3) NA 20.7
2 > 20 (17.4) > 20 (10.3) 21.4
3 13.5 13.00 19.7
4 > 20 (11.6) > 20 (21) 23.3
5" NA NA 21.3
AZT 500
Values are IC50 concentration in tg/mL. Percent inhibition observed is the value in brackets.
NA Not active inhibition < or 5% at 20 tg/mL.
*The sample was not active but had a significant unique impact on growth behaviour of U87-MG cells at 20
and 10 lag/mL. AZT Azido-thymidme
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